Projecting the Future Diabetes Population Size and Related Costs for the U.S.

OBJECTIVE We developed a novel population-level model for projecting future direct spending on diabetes. The model can be used in the federal budget process to estimate the cost implications of alternative policies. RESEARCH DESIGN AND METHODS We constructed a Markov model simulating individuals' movement across different BMI categories, the incidence of diabetes and screening, and the natural history of diabetes and its complications over the next 25 years. Prevalence and incidence of obesity and diabetes and the direct spending on diabetes care and complications are projected. The study population is 24- to 85-year-old patients characterized by the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey and National Health Interview Survey. RESULTS Between 2009 and 2034, the number of people with diagnosed and undiagnosed diabetes will increase from 23.7 million to 44.1 million. The obesity distribution in the population without diabetes will remain stable over time with ∼65% of individuals of the population being overweight or obese. During the same period, annual diabetes-related spending is expected to increase from $113 billion to $336 billion (2007 dollars). For the Medicare-eligible population, the diabetes population is expected to rise from 8.2 million in 2009 to 14.6 million in 2034; associated spending is estimated to rise from $45 billion to $171 billion. CONCLUSIONS The diabetes population and the related costs are expected to at least double in the next 25 years. Without significant changes in public or private strategies, this population and cost growth are expected to add a significant strain to an overburdened health care system.

[1]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[2]  M. Chin,et al.  Improving and Sustaining Diabetes Care in Community Health Centers With the Health Disparities Collaboratives , 2007, Medical care.

[3]  R. Helms Implications of Population Growth on Prevalence of Diabetes: A Look at the Future , 1992, Diabetes Care.

[4]  M. Engelgau,et al.  Improvements in Diabetes Processes of Care and Intermediate Outcomes: United States, 19882002 , 2006, Annals of Internal Medicine.

[5]  Using clinical information to project federal health care spending. , 2009, Health affairs.

[6]  R. Devol,et al.  An Unhealthy America:The Economic Burden of Chronic Disease , 2007 .

[7]  W. O'Fallon,et al.  Chronic renal failure in non-insulin-dependent diabetes mellitus. A population-based study in Rochester, Minnesota. , 1989, Annals of internal medicine.

[8]  D. Armstrong,et al.  Preventing foot ulcers in patients with diabetes. , 2005, JAMA.

[9]  W. O'Fallon,et al.  Survival and recurrence after first cerebral infarction , 1998, Neurology.

[10]  S. Saydah,et al.  Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. , 2004, JAMA.

[11]  Alan Brennan,et al.  Computer Modeling of Diabetes and Its Complications , 2007, Diabetes Care.

[12]  M. Davidson The disproportionate burden of diabetes in African-American and Hispanic populations. , 2001, Ethnicity & disease.

[13]  C. Neslusan,et al.  Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes. , 2003, Diabetes care.

[14]  R. Stevens,et al.  UKPDS 60: Risk of Stroke in Type 2 Diabetes Estimated by the UK Prospective Diabetes Study Risk Engine , 2002, Stroke.

[15]  R. Holman,et al.  A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68) , 2004, Diabetologia.

[16]  L S Geiss,et al.  Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. , 2001, Diabetes care.

[17]  A. Zbrozek,et al.  Model of Complications of NIDDM: I. Model construction and assumptions , 1997, Diabetes Care.

[18]  R. Holman,et al.  The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). , 2001, Clinical science.

[19]  Bruce H. R. Wolffenbuttel,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.

[20]  David O Meltzer,et al.  The cost-effectiveness of improving diabetes care in U.S. federally qualified community health centers. , 2007, Health services research.

[21]  H. King,et al.  Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections , 1998, Diabetes Care.